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RESUM
En aquest article volem revisar la diversitat dels mecanismes moleculars suposadament res-
ponsables del creixement independent d’andrògens del càncer de pròstata. Es demostra que
alguns càncers de pròstata que escapen de la teràpia endocrinològica estan compostos per cèl-
lules sensibles als andrògens.
Ens centrarem en els resultats del nostre laboratori i en els d’altres grups de recerca que sugge-
reixen el mateix concepte nou: el comportament del càncer de pròstata refractari als andrògens
està associat a una resposta invertida de les cèll. ules als andrògens. Hem observat un alentiment
paradoxal en el creixement de diverses línies cell. ulars induït pels andrògens. Aquestes línies
cell. ulars provenen de les cèll. ules LNCaP, ja sigui per evolució espontània o per cultiu crònic
en un medi sense andrògens. La línia ARCaP (androgen-reverted carcinoma of the prostate) va ser
establerta a partir de l’ascitis d’un pacient amb càncer de pròstata avançat. Els tumors que va-
ren créixer a partir d’aquestes cèll. ules reverteixen, encara que transitòriament, en el tractament
androgènic. Volem suggerir que la castració podria permetre la proliferació de les cèll. ules que
eren paradoxalment alentides pels andrògens i que aquesta reacció invertida als andrògens po-
dria ser el possible mecanisme pel qual el càncer de pròstata deixa de respondre a la teràpia
hormonal. Aquests resultats aportarien unes bases racionals per a comprendre el tractament
antiandrogènic intermitent.Paraules clau: pròstata, andrògens, antiandrògens, resistència, inhibició.
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SUMMARY
In this paper we survey the diversity of the molecular mechanisms suspected to be respon-
sible for the androgen-independent growth of prostate cancer. It has been shown that some
prostate cancers, which escape endocrine therapy, are composed of androgen-sensitive cells.
We focus on the results from our laboratory and from a few others that suggest a new con-
cept: that the androgen-refractory behavior of prostate cancer may be associated with an in-
verted response to androgens by cells. The proliferation of several cell lines was paradoxically
slowed by androgens. In the afore-mentioned studies, a series of these cell lines arose from
the LNCaP cell line, either spontaneously or after culturing them chronically in androgen-poor
culture medium. The ARCaP (androgen-reverted carcinoma of the prostate) was established
from the ascites of a patient with advanced prostate cancer. Usually, tumors grown from such
cells regress, albeit transiently, under androgen treatment. It has been suggested that castra-
tion could allow the proliferation of cells that are paradoxically slowed by androgens and that
the inverted response to androgens could possibly be a mechanism, by which prostate cancer
escapes from endocrine therapy. These results provide the rationale for intermittent treatment.Keywords: prostate, androgen, anti-androgen, resistance, inhibition.
PROSTATE CANCER CELLS AS
ANDROGEN TARGETS
In industrialized countries, prostate carci-
noma is the second most prevalent malignant
tumor in men after skin cancer. It accounts
for up to 33% of all male cancers (Carducci
and Carroll, 2005). At age 85, the cumula-
tive risk of malignancy ranges from 0.5% to
20% worldwide (Gronberg, 2003). In the year
2000, the mortality rates were 15 and 19 per
100,000 men in Spain and France, respectively
(Crawford, 2003). Moreover, its incidence is
expected to rise with the advancing age of
the population. It is encouraging to know that
screening and appropriate treatments are able
to decrease prostate cancer mortality (Etzioni
et al., 2003; Labrie et al., 2004).
The prostate depends on endogenous an-
drogens, mainly DHT, for growth and dif-
ferentiation. Growth stimulation results from
the activation of cell proliferation and the in-
hibition of apoptosis. Androgens also play a
central role in prostate cancer development
(DeMarzo et al., 2003; Feldman and Feld-
man, 2001; Kokontis and Liao, 1999), in con-
junction with diet, lifestyle and genetic back-
ground (Nelson et al., 2003). The chemical
prevention of prostate cancer has been at-
tempted with some success by blocking the
last step of DHT production at the level
of testosterone reduction using 5-alpha re-
ductase. However, it is not currently rec-
ommended, since the trial has raised some
doubts about the risk of increasing the inci-
dence of high-grade tumors (Lieberman, 2003;
Scardino, 2003; Thompson et al., 2003). The
adjuvant treatments most currently used for
advanced prostate cancers are aimed at block-
ing androgen effects through androgen de-
privation and/or the administration of an-
drogen receptor (AR) antagonists. Although
many tumors initially regress, most of them
relapse, i.e., they cease to respond and prolif-
erate, in spite of continued treatment. Such tu-
mors are referred to as androgen-independent
prostate cancer (AIPC), hormone-refractory,
hormone-insensitive, hormone-relapsed or
hormone-resistant. However, it must not be
forgotten that such tumors are composed of
cells that are indeed responsive to androgens
and anti-androgens (see below).
A large majority of the biological effects of
androgens require classical AR that belongs
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to a wide family of ligand-dependent tran-
scription factors (Heinlein and Chang, 2004).
These receptors also bind various compounds
and, as a result, exhibit androgen-type ef-
fects. Ligand binding changes AR conforma-
tion, similar to the way in which a hand
changes the shape of a glove. The resulting
AR activation includes the dissociation from
heat shock protein, homodimerization, phos-
phorylation, and finally, the binding to chro-
matin. The homodimer, charged with ligand,
binds to short sequence(s) of DNA, called the
androgen-response element (ARE), which is
located upstream of the initiation site of tran-
scription or the DNA-binding proteins, lo-
cated in the region. In both cases, the dimer
recruits specific co-factors. Some of them dis-
play enzyme activity that controls the open-
ing / condensation of chromatin, in order
to facilitate or prevent the formation of the
initiation complex for transcription. The tran-
scription of androgen-responsive genes is up-
or down-regulated, according to the set of
co-factors that have been recruited and are
already located on the promoter. Pure antago-
nists bind to AR and do not lead to gene tran-
scription, because the co-inhibitors are also
recruited. Mixed agonist-antagonist ligands,
called SARM —Specific Androgen Receptor
Modulator, (Negro-Vilar, 1999)—, behave as
agonists in some cells or tissues and as an-
tagonists in others, depending on the DNA
alterations (mutations and epigenetic mod-
ifications) and the cell signaling, triggered
by membrane receptors. As a result, all of
the following contribute to the type of re-
action observed in response to endogenous
or exogenous compounds: the AR concentra-
tion, the AR-ligand induced fit, the concen-
tration, the activity and combination of co-
factors, and the membrane signals. Non pri-
mary genomic actions are also known. They
involve classical AR and interactions with
proteins, involved in the intracellular signal-
ing triggered at the membrane level. Andro-
gens can also modulate the SHBG signaling
from its membrane receptor, thought to be
a G-protein coupled receptor (Rosner et al.,
1999). The modification of any compound in-
volved in androgen action is potentially a de-
terminant for hormone resistance.
MECHANISMS
OF TUMOR “RESISTANCE”
Five main types of pathways for the de-
velopment of AIPC have been categorized
(Edwards and Bartlett, 2005a, b; Feldman and
Feldman, 2001; Grossmann et al., 2001). 1) The
hypersensitive pathway refers to situations in
which the response to androgens by cells is
higher than expected, when taking into ac-
count the quantity of androgens added to
the experimental model or measured in the
blood. Cells with such a pathway can grow
in a low androgen environment, such as that
encountered in castrated patients. This path-
way could result from the following alter-
ations: an increase in AR concentration, which
is sometimes the consequence of AR gene am-
plification (Koivisto et al., 1997), the presence
of high-affinity AR encoded by a mutated
AR gene (somatic mutation), the expression
of a particular hyper-active set of co-factors
(Gregory et al., 2001), and a local augmen-
tation of DHT production, brought about by
an increase of 5-alpha reductase activity. It
is of interest to note that a modest increase
in AR is a molecular determinant for resis-
tance to anti-androgen therapy (Chen et al.,
2004; Isaacs and Isaacs, 2004). 2) The promis-
cuous pathway is mainly observed in cells with
particular missense mutations of the AR gene
(Linja and Visakorpi, 2004; Veldscholte et al.,
1990). These mutations increase the affinity
for various ligands and broaden the list of
compounds able to bind and activate AR.
Hence, adrenal androgens, glucocorticoids,
progestins, and the antagonist flutamide bind
to different mutated AR and stimulate cell
proliferation. The so-called promiscuous AR
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can explain both the rise of PSA in patients
treated with flutamide and glucocorticoids,
as well as explaining the improvement (tran-
sient) sometimes observed following the ar-
rest of treatment. Co-factor alterations may
be involved in these unexpected biological
responses. 3) The outlaw pathway is AR de-
pendent, but AR-ligand independent. In this
case, the AR-dependent gene expression is
mainly enhanced via the phosphorylation of
AR and its co-factors. Cytokines such as IL6
(Culig et al., 1996; George et al., 2005), growth
factors such as IGF-1, EGF, KGF, and heureg-
ulin (Gioeli, 2005; Gregory et al., 2005), neu-
ropeptides and adrenomedullin (Rocchi et al.,
2001), and the over-expression of HER2/neu
can induce androgen effects. The fact that anti-
androgens inhibit the effects of cytokines and
growth factors, but not those resulting from
the over-expression of HER2/neu, suggests
that different domains of AR are involved
in the cross-talk between AR and membrane
receptor cell signaling. HER2/neu activates
the MAP kinase and the protein kinase B
(AKT) pathways. The AKT pathway is down-
regulated by a PIP3 phosphatase, encoded by
PTEN. Therefore, a loss-of-function mutation
of PTEN enhances the AR-dependent path-
way. 4) The by-pass pathway is independent
of AR and AR ligands. When tumors escape
treatment, there is more cell division than cell
death, e.g., by apotosis. The low apoptotic ac-
tivity is in correlation with the increase of
the anti-apoptotic proteins, bcl-2, bcl-x, clus-
terin (So et al., 2005), and c-FLIP (Gao et al.,
2005). In pathways 1 to 4, cells are supposed
to become resistant under treatment by var-
ious mechanisms: the accumulation of muta-
tions, a change in the epithelium/stroma ratio
(Lee and Tenniswood, 2004), a change in the
local concentrations of hormones, cytokines,
and growth factors, etc. 5) The lurker cell path-
way is clearly different from the four previous
pathways. The lurker pathway postulates that
true androgen-resistant cells may be present
in the tumors before treatment has started.
This could occur when stem cells, known to
be androgen resistant, are transformed. Sev-
eral pathways can function simultaneously,
since prostate cancer cells are very heteroge-
neous (Shah et al., 2004). Other mechanisms
may exist, e.g., increased angiogenesis (Gus-
tavsson et al., 2005) and an inversion of the
response to androgens (see below). A set of
genes that may be involved in the progression
to androgen independence has recently been
described (Pfundt et al., 2005; Shi et al., 2004).
A NEW PUTATIVE MECHANISM
OF “TUMOR RESISTANCE”..
THE AR-DEPENDENT
UPSIDE-DOWN PATHWAY
The proliferation of several cell lines was
paradoxically slowed by androgens. First, a
series of such cell lines arose from the LNCaP
cell line, found in a lymph node of a pa-
tient treated for advanced prostate cancer
(Horoszewicz et al., 1983). The switch oc-
curred either spontaneously as LNCaP-R/R2
(Joly-Pharaboz et al., 1995), or it occurred af-
ter being cultured chronically in androgen-
poor culture medium, such as LNCaP 104-R
(Kokontis et al., 1994) and MOP (Joly-Phara-
boz et al., 2000) or JAC cells (unpublished).
These cells expressed the promiscuous T877A
mutated AR. Second, another source of an-
drogen-repressed cells (ARCaP, for androgen
reverse carcinoma of prostate) was the as-
cites fluid of a patient with advanced prostate
cancer (Zhau et al., 1996). The pathway that
sustained these paradoxical effects may be
referred to as the upside-down pathway in
Feldman’s terminology, which points out that
androgens, instead of stimulating, as shown
in wild-type LNCaP, inhibit cell prolifera-
tion. In fact, the differences between wild-type
LNCaP and LNCaP variants are not so sim-
ple. The dose-dependent response was bell-
shaped in the wild-type, with a maximum of
around 0.1 nM R 1881, while there was a dose-
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dependent inhibition of proliferation in other
cells (ED50 = 0.1 nM R1881). Concerning the
dose-dependent inhibition, DHT was nearly
as potent as R 1881, indicating that the re-
sponse occurred in the physiological range of
the androgens. Simultaneously, the cell cycle
was blocked at G0-G1 (Joly-Pharaboz et al.,
2000, 1995; Zhau et al., 1996), and small spher-
ical cell fragments appeared around the MOP
cells. This fragmentation has been confirmed
by flow cytometry (not published). In addi-
tion, a ligand-induced apoptosis was shown
in MOP cells, but not in R2 cells. Surprisingly,
androgen treatment lead to a frank cell hy-
pertrophy, as the cell content of proteins and
RNA was increased. Several molecular deter-
minants of the paradoxical response to andro-
gens were sought. We did not find any quanti-
tative or qualitative differences in AR between
androgen-stimulated and androgen-inhibited
cells. There was no increase, even modest,
in AR concentration. MOP and R2 cells con-
tained the same mutated AR as LNCaP cells.
The same poly CAG polymorphism in exon
1 was found in the AR gene of MOP cells
and LNCaP cells. No new mutation was found
in the last seven exons of the AR gene (Joly-
Pharaboz et al., 1995, 2000;). The same pat-
tern of ligand affinities for AR was shown
in R2 and LNCaP cells (Joly-Pharaboz et al.,
1995), and there was a rather good correla-
tion between the affinity of the ligands for AR
(R 1881, DHT, cyproterone acetate, estradiol,
progesterone, and R 5020) and their efficacy
in inhibiting cell proliferation. The paradoxi-
cal response to androgens did not appear to
be associated with any change in the levels
of mRNA encoding the following co-factors:
ARA 70, SRC-1, CBP, TIF-2 RAC3/ACTR, and
SMRT (not published). The androgen regula-
tion of several genes was not modified when
cells switched from the androgen-positive
to the androgen-negative control of prolif-
eration. For example, androgens increased
the PSA and VEGF secretions by MOP cells
dose-dependently (Joly-Pharaboz et al., 2000;
Kalach et al., 2005) and unpublished results).
Androgens down-regulated c-myc RNA in
the three cell lines LNCaP, MOP and R2 dose-
dependently (Foury et al., 1998). More re-
cently, we have shown that estradiol, but not
the synthetic estrogen DES, exerts androgen-
like effects through mutated AR binding and
not through ER binding (Kalach et al., 2005).
Androgens inhibit the proliferation in vivo
of those cells that are also inhibited in culture.
This conclusion was drawn from experiments
performed on nude mice grafted sc. with var-
ious cells. The tumors developing from such
cells regressed transiently under androgen
treatment (Joly-Pharaboz et al., 2000; Umekita
et al., 1996). In our study, testosterone enan-
thate slowed the take of the graft, and more
interestingly, led to tumor regression, without
any exceptions out of more than one hun-
dred tumors treated to date. Since the tumors
regressed under treatment (some tumors be-
came non-palpable under the skin of the nude
mice), the androgens clearly increased cell
death. However, due mainly to the fact that
the tumors presented large zones of necro-
sis, we were unable to demonstrate any in-
crease in cell apoptosis in vivo. As observed in
cells in culture, the intact up-regulation of sev-
eral genes (PSA, VEGF) by androgens was
also intact in the animal tumors. All of the
MOP tumors escaped androgen treatment;
therefore, the androgen used was not a magic
bullet against MOP-like cells. TE cells, cul-
tured from tumors that escaped treatment,
were less responsive to androgens than the
MOP cells, which had given rise to the tumor.
However, the cells recovered a response to an-
drogens, similar to that of parental MOP cells
after ten subcultures.
CONCLUSION
From this short survey, it appears that cells,
used as models for studying the molecular
determinants for the resistance of advanced
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prostate cancer to endocrine therapy, do con-
tain functional AR. Although the altered path-
way did involve frequent abnormalities in
AR-dependent signaling, the sole increase
in anti-apoptotic proteins may by-pass the
consequences of an androgen blockade. True
androgen-resistant AR-negative cells, such as
PC3 and DU-145, have been established from
metastases of human prostate cancer; and,
prostate stem cells may be a source of lurker
cells. The participation of androgen-resistant
cells in the phenomenon of tumor escape from
hormone therapy remains to be specified.
The molecular determinants for the inver-
sion of response to androgens remain to be
found. This information may provide us with
an answer as to why the paradoxical effects
of androgens have not been mentioned so far,
to the best of our knowledge, in any of the
reviews on androgen and anti-androgen resis-
tance. It is our opinion that such an inversion
offers an explanation for tumor escape from
treatment. Although androgen-repressed cells
also escape from androgen treatment in an
experimental model, the androgen-induced
inhibition of cell proliferation is a further ra-
tionale for intermittent therapy, i.e., the suc-
cession of periods of androgen privation and
androgen or estrogen administration (Peyro-
maure et al., 2005; Rashid and Chaudhary,
2004). Since the benefits of endocrine ther-
apy on advanced prostate cancer are tran-
sient, new drugs or new schedules of treat-
ments are required. Encouraging results from
chemotherapy have been recently reported
(Hussain et al., 2005; Petrylak, 2005; Petrylak
et al., 2004). We would like to stress that re-
verted hormone action is not as strange as it
may appear at first glance. Indeed, in a follow-
up to some work done with José Sáez, we
were able to show that estradiol, known to in-
duce the hypertrophy of the anterior pituita-
ry, inhibited the growth of some rat pituitary
tumor cells (Morel et al., 1982). In addition,
the growth of several cell lines isolated from
the human breast cancer MCF-7 cells, was
inhibited by estradiol at concentrations that
stimulated the growth of the parental MCF-7
(Lewis et al., 2005; Uchiumi et al., 1991).
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